December 3, 2012 AstraZeneca AB SE-431 83 Mölndal Sweden Re: Out-License Agreement by and between AstraZeneca AB (“AstraZeneca”) and Flexion Therapeutics AG (“Flexion”) effective June 12, 2009 (the “Agreement”) Dear Sirs,Out-License Agreement • January 8th, 2014 • Flexion Therapeutics Inc • Pharmaceutical preparations
This letter sets forth our mutual understanding and certain amendments to the Agreement with respect to Licensed Products and Compounds (the compound known as FX005 ([…***…])). Capitalized terms used herein and not otherwise defined shall be given the meaning in the Agreement. In consideration of the rights and covenants of the Parties the sufficiency of which is acknowledged, Flexion and AstraZeneca agree as follows:
Teva PharmaceuticalsOut-License Agreement • May 7th, 2015
Effective December 3, 2012, we entered into a license and supply agreement with ABIC Marketing Limited, a subsidiary of Teva Pharmaceuticals (“ABIC”). Under the agreement, we granted ABIC exclusive rights to seek marketing approval in Israel for our NeuVax product candidate for the treatment of breast cancer following its approval by the FDA or the European Medicines Agency, and to market, sell and distribute NeuVax in Israel assuming such approval is obtained. ABIC’s rights also include a right of first refusal in Israel for all future indications for which NeuVax may be approved.
